TNF Bound to PEGylated Gold Nanoparticles: a Platform for a Family of Cancer Nanomedicines
President and CEO
Cytimmune Sciences Inc.
Prior to co-founding CytImmune in 1988, Dr. Tamarkin was Head of the Psychoneuroimmunology Program at the National Institute of Mental Health. Dr. Tamarkin also held research scientist positions in the National Cancer Institute and the National Institute of Child Health and Human Development. He also was an Associate Research Professor of veterinary medicine at the University of Maryland, College Park. His publications include articles in the areas of cancer, pediatrics and psychiatry. He is the co-inventor of the colloidal gold-based technology covered by thirty three issued patents and a number of pending patents. Dr. Tamarkin led CytImmune from its initial focus as a diagnostic company to its current focus on therapeutics. Dr. Tamarkin graduated from S.U.N.Y at Stony Brook with a B.S. in biology and received his Ph.D. from the University of Connecticut.